Adenosine Production Inhibitor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adenosine production inhibitor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adenosine Production Inhibitor Today - Breaking & Trending Today

Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $10.00

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) had its target price lifted by LADENBURG THALM/SH SH from $4.00 to $10.00 in a research report released on Tuesday morning, The Fly reports. A number of other equities analysts also recently commented on CRVS. Mizuho restated a neutral rating and issued a $3.50 target price on shares of […] ....

Corvus Pharmaceuticals Stock Performance , Corvus Pharmaceuticals Company Profile , News Ratings For Corvus Pharmaceuticals Daily , Discovery Capital Management , Corvus Pharmaceuticals , Cantor Fitzgerald , Renaissance Technologies , Corvus Pharmaceuticals Inc , Institutional Trading Of Corvus Pharmaceuticals , Get Rating , Capital Management , Sigma Advisers , Sigma Investments , Adenosine Production Inhibitor , Corvus Pharmaceuticals Daily , Nasdaq Crvs , Boost Price Target , Ladenburg Thalm Sh ,

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Update

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 455,500 shares, a growth of 209.2% from the April 30th total of 147,300 shares. Approximately 1.3% of the shares of the company are sold […] ....

Corvus Pharmaceuticals Inc , News Ratings For Corvus Pharmaceuticals Daily , Discovery Capital Management , Renaissance Technologies , Cantor Fitzgerald , Vanguard Group Inc , Corvus Pharmaceuticals Stock Performance , Hedge Funds Weigh In On Corvus Pharmaceuticals , Corvus Pharmaceuticals , Get Rating , Capital Management , Two Sigma Advisers , Sigma Advisers , Adenosine Production Inhibitor , Corvus Pharmaceuticals Daily , Nasdaq Crvs ,

Corvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research report report published on Thursday morning. The firm issued a hold rating on the stock. CRVS has been the subject of several other research reports. Cantor Fitzgerald raised their price target on Corvus Pharmaceuticals from $2.00 to $4.00 in a […] ....

Institutional Trading Of Corvus Pharmaceuticals , News Ratings For Corvus Pharmaceuticals Daily , Discovery Capital Management , Corvus Pharmaceuticals , Corvus Pharmaceuticals Trading , Renaissance Technologies , Corvus Pharmaceuticals Inc , Cantor Fitzgerald , Corvus Pharmaceuticals Company Profile , Get Rating , Capital Management , Sigma Advisers , Sigma Investments , Adenosine Production Inhibitor , Corvus Pharmaceuticals Daily , Nasdaq Crvs , Initiated Coverage , Stocknews Com ,

Linda Grais Buys 10,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) Director Linda Grais bought 10,000 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were bought at an average cost of $2.45 per share, with a total value of $24,500.00. Following the completion of the transaction, the director now owns 10,000 shares […] ....

Linda Grais , Morgan Stanley , Securities Exchange Commission , Quarter For Corvus Pharmaceuticals , Cantor Fitzgerald , Corvus Pharmaceuticals Company Profile , Corvus Pharmaceuticals Stock , Institutional Trading Of Corvus Pharmaceuticals , Corvus Pharmaceuticals , News Ratings For Corvus Pharmaceuticals Daily , Corvus Pharmaceuticals Inc , Discovery Capital Management , Get Rating , Director Linda Grais , Exchange Commission , Capital Management , Sigma Advisers , Two Sigma Investments , Sigma Investments , Adenosine Production Inhibitor , Corvus Pharmaceuticals Daily , Nasdaq Crvs , Insider Trading , Nsider Trades ,

Linda Grais Purchases 10,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) Director Linda Grais acquired 10,000 shares of the business’s stock in a transaction on Monday, May 15th. The stock was purchased at an average cost of $2.45 per share, with a total value of $24,500.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s […] ....

Linda Grais , Institutional Trading Of Corvus Pharmaceuticals , Corvus Pharmaceuticals Stock Performance , Corvus Pharmaceuticals Company Profile , Quarter For Corvus Pharmaceuticals , Corvus Pharmaceuticals Inc , Corvus Pharmaceuticals , Securities Exchange Commission , News Ratings For Corvus Pharmaceuticals Daily , Vanguard Group Inc , Renaissance Technologies , Acadian Asset Management , Cantor Fitzgerald , Get Rating , Director Linda Grais , Exchange Commission , Sigma Advisers , Sigma Investments , Asset Management , Adenosine Production Inhibitor , Corvus Pharmaceuticals Daily , Nasdaq Crvs , Insider Trading , Nsider Trades ,